Full-Time

Regional Lead Real Estate & Workplace Solutions

Posted on 10/31/2025

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

Maidenhead, UK + 1 more

More locations: United Kingdom

In Person

Category
Real Estate (2)
,
Requirements
  • Bachelor’s degree required.
  • English proficiency required.
  • Proven experience in delivery of Workplace, Real Estate and Facilities Services.
  • Proven experience leading complex teams with diverse direct reports and stakeholders.
  • Ability to toggle between being strategic while delivering tactically.
  • Experience in service delivery in various site environments (i.e. Manufacturing, Office, Labs).
  • Demonstrated knowledge of compliance requirements of assigned specific contractual relationships.
  • Ability to define problems, collect data, establish facts, solve problems, make recommendations, and draw valid conclusions in a timely and accurate manner.
  • Strong communication skills, oral and written.
  • Sound judgment and reasoning skills.
  • Ability to prioritize and successfully manage multiple projects/deadlines simultaneously.
  • Strong knowledge of MS Office applications.
Responsibilities
  • Partners with external Real Estate Partners to drive solutions and manage portfolio pipeline and projects
  • Serve as a strategic advisor to the Global Head of WREF, helping to align the organization with corporate goals and drive continuous improvement
  • Build and maintain relationships with all appropriate internal business stakeholders to ensure the real estate portfolio in the EMEA aligns with the needs of the business.
  • Ensure alignment with the Global RE program yet allowing for regional and site influences.
  • Provide CSL Regional Leadership with wholistic strategic real estate solutions including but not limited to: location advisory, employee commute and demographics studies, market options comparison analyses, financial assessment, industry best practices, metrics, and compile into business cases along with socialization for decision making. Then leading the project management through Day One occupancy and operations thereafter
  • Other common responsibilities include researching and discussing property maintenance costs and possible renovations, networking with local businesses, negotiating between buyers and sellers, overseeing property inspections, review of leases and contracts, and facilitating final transactions.
  • Align and support the management of the Global Real Estate portfolio and software tracking mechanisms.
  • Maintain SLAs, KPIs and processes to ensure that financial milestones, contractual obligations, compliance requirements and milestone liabilities associated with third party service contracts are appropriately managed.
  • Partner with the Global Head of WREF in developing key operational frameworks, governance structures, and strategic priorities that will drive the success of the Global Real Estate function.
  • Collaborate with internal CSL clients and organizations to provide solutions that produce meaningful change promoting innovation and collaboration within the work environment.
  • Ensure alignment with the Global workplace strategies yet allowing for regional and site influences.
  • Working closely with the global and change committees as well as HR, the Regional Lead develops solutions that aim to align the work environment and work practices with organizational business goals and objectives at the site, campus and portfolio levels.
  • Solutions can be inclusive of the “business case for change” and the development and roll out of change management programs.
  • The Regional Lead should be well versed with working experience in the areas of occupancy planning, design, functional program and workplace standards and metrics development incorporating both traditional and alternative workplace strategies.
  • Build and maintain relationships with all internal stakeholders to ensure the service delivery performance of the Facility IFM Services exceeds expectations. Collaborate with and act as a point of contact for global functional leaders across Sourcing/ Procurement, Quality, Legal. EHS, Finance, Business Unit Leads etc.
  • Supervise the site IFM Lead and Facilities Coordinator to drive, relationships, budget, and planning. Be the escalation point for issues with relation to contractors and vendors and secure resolution.
  • Monitor contractual changes, provide guidance on the implementation of any required changes, and proactively integrate new requirements into compliance programs.
  • Consults on Facilities budget. Oversee and manage finances, ensuring cost-effectiveness and forecasting.
  • Balance risk and compliance needs with business strategies to guide decisions for related Facilities requests. Ensure adherence to pertinent regulatory requirements and to departmental policies, practices, and procedures [SOPs, safety procedures, etc.].
  • Ensure delivery of value realization and monitor overall performance against developed SLAs, KPIs and metrics.
  • Utilizing an SRM (Supplier Relationship Management) approach, manage category IFM supplier contracts, relationships, for the EMEA portfolio. Be the escalation point for issues with relation to contractors and vendors and secure resolution.
  • Interact and influence various site GMs and Facilities leads to establish and drive an appropriate ongoing IFM Committee/Forum.
  • Ensure alignment with the Global IFM program yet allowing for regional and site requirements.
  • Monitor contractual changes, provide guidance on the implementation of any required changes, and proactively integrate new requirements into compliance programs.
  • Develop, implement, and support operational plans and share best practices as it relates to policies, processes, and governance.
  • Identify common operational and business needs across sites, and work to address them through the global program.
  • Identify the areas of IFM service delivery for which compliance is required.
  • Ensure delivery of value realization and monitor overall performance against developed KPIs and metrics.
  • Maintain KPI's and processes to ensure that financial milestones, contractual obligations, compliance requirements and milestone liabilities associated with third party service contracts are appropriately managed.
Desired Qualifications
  • Master’s degree preferred.
  • Professional Certification(s) preferred.

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Simplify Jobs

Simplify's Take

What believers are saying

  • HEMGENIX gene therapy sustains 37% factor IX levels through four years post-2025 data.
  • KOSTAIVE self-amplifying mRNA COVID vaccine approved by EC February 2025.
  • VarmX $2.2B acquisition option expands bleeding disorder pipeline in 2026.

What critics are saying

  • Seqirus separation triggers $500M charges and 14% revenue loss from Pentagon mandate scrap.
  • Grifols opens 20 plasma centers by 2027, eroding CSL Behring's immunoglobulin share.
  • Novartis Fabhalta displaces CSL Vifor's $1.5B nephrology revenues within 12 months.

What makes CSL unique

  • CSL Behring leads plasma-derived therapies for haemophilia and immunodeficiencies.
  • CSL Seqirus dominates influenza vaccines with global production scale.
  • CSL Vifor specializes in iron deficiency and nephrology treatments post-2022 acquisition.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Company News

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

Stock Titan
Aug 1st, 2025
Automated Logic Acquires Control Solutions Ltd.

Automated Logic – Canada, Ltd. (ALC), part of Carrier Global Corporation, has acquired Control Solutions, Ltd. (CSL), an independent provider of building-automation systems in Coquitlam, British Columbia. This acquisition establishes ALC's first field office in Vancouver, expanding its presence in Western Canada and enhancing its ability to deliver intelligent building solutions in high-growth sectors across British Columbia.

PharmiWeb.com
Apr 14th, 2025
First Patient Treated With Hemgenix® (Etranacogene Dezaparvovec) Gene Therapy For Haemophilia B In Austria

Vienna, Austria – 9 April 2025 - CSL Behring Austria today announced that the first haemophilia B patient in Austria was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Comprehensive Care Center of the University Hospital of Medicine Vienna.HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1“It is a great opportunity for people with hemophilia B to live a symptom-free life for many years,” explains hematologist Univ.-Prof. Priv.-Doz. Dr Cihan Ay from the Medical University of Vienna, University Clinic for Internal Medicine I Clinical Department for Hematology and Hemostaseology."For the community of affected patients and their families, this represents an enormously significant milestone: the ability to treat hemophilia with gene therapy, and the fact that this option is now available in Austria, is something our community has been eagerly anticipating and hoping for over decades," says Thomas Schindl, MA, Chairman of the Austrian Hemophilia Society (ÖHG)."We are proud and grateful to offer haemophilia B patients in Austria a treatment option that has the potential to transform their lives," said Dr Beate Natmessnig, Managing Director of CSL Behring Austria. "This achievement is the result of outstanding regional and national collaboration among all parties involved and is a strong testament to Austria's innovative capabilities."HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022

PharmiWeb.com
Apr 3rd, 2025
Csl Behring And Gkv-Spitzenverband Agree On Reimbursement Price For Hemgenix® – Europe'S First Gene Therapy For Haemophilia B

Marburg, Germany, 2 April 2025 – CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX®. This agreement marks the availability of the first gene therapy approved in Europe for haemophilia B under an innovative, national, success-based reimbursement model, being implemented for the first time in Germany.HEMGENIX® represents significant progress in the treatment of haemophilia B. The aim of this one-time gene therapy is to eliminate the need for regular factor IX infusions, thereby offering patients the possibility of more freedom from prophylaxis and significantly improving their quality of life.1-4 This development not only provides substantial relief for those affected but also has the potential to reduce long-term costs for the healthcare system.‘The performance-based payment model at national level which was agreed with the GKV-Spitzenverband is unique in Germany. It addresses key reimbursement challenges, such as the question of long-term efficacy, which is inherent for any one-time therapy. Reimbursement is linked to treatment success of the individual patient,’ explains Stefan Neudoerfer, CSL Behring's chief negotiator in Germany.Moreover, this reimbursement model reflects the high therapeutic and innovative value of HEMGENIX® and sets new standards for integrating innovative gene therapies into the German healthcare system.‘The agreement on the reimbursement price of HEMGENIX® is a decisive step for the care of people with haemophilia B in Germany. It enables access to a groundbreaking therapy and recognises the long-term medical and economic benefits of gene therapy,’ explains Christian Wieszner, Managing Director of CSL Behring Germany.With this agreement, CSL Behring is underlining its commitment to innovative therapies that sustainably improve the lives of patients

INACTIVE